UW OncoPlex Cancer Gene Panel
- Lab Name
- UW OncoPlex Cancer Gene Panel
- Lab Code
- Epic Ordering
Order using "UW Genetics and Solid Tumor Test Request"
See tip sheet for more information (internal link).
UW-OncoPlex™ is a multiplexed mutation assay for tumor tissue that assesses mutations >350 genes related to cancer treatment, prognosis, or diagnosis (listed below).
Please note that UW-OncoPlex™ is intended for solid tumors. For testing related to myeloid and lymphoid disorders, please order Heme Gene Panel by NGS [HCAPA]. For testing related to acute myeloid leukemias and myelodysplastic syndromes, please order Myeloid Gene Panel by NGS [HCAPMY].
The test uses next-generation "deep" sequencing to detect most classes of mutations, including single nucleotide variants, small insertions and deletions (indels), gene amplifications, and selected gene fusions.
Microsatellite instability (MSI) status and total mutation burden (TMB) is reported for relevant cancer cases.
This test is designed to detect somatic mutations in cancer and is not designed to detect germline (heritable) mutations.
To request testing for one individual gene in the panel, see information for UW OncoPlex Single Gene [OPG].
- Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet 2010, 11:31-46. 19997069
- Pritchard CC, et al. Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. J Mol Diagn 2014, 16:56-67. 24189654
- Salipante SJ, Scroggins SM, Hampel HL, Turner EH, and Pritchard CC. Microsatellite instability detection by next generation sequencing. Clin Chem 2014, 60:1192-9. 24987110
- Kuo AJ, et al. Validation and implementation of a modular targeted capture assay for the detection of clinically significant molecular oncology alterations. Pract Lab Med. 2020 Feb 3;19:e00153. PMID: 32123717
- Perrone ME, et al. Validating cell-free DNA from supernatant for molecular diagnostics on cytology specimens. Cancer Cytopathol. 2021 Dec;129(12):956-965. PMID: 34265180
- ABCA10, ABCA12, ABCC9, ABL1, ABL2, ACVR1, AKAP9, AKT1, AKT2, AKT3, ALK, ANGPTL1, ANKRD26, APC, AR, ARAF, ARID1A, ARID1B, ASPH, ASXL1, ASXL2, ATM, ATR, ATRX, AURKA, AURKB, AXIN2, AXL, BABAM1, BAK1, BAP1, BARD1, BCL2, BCL2L11, BCOR, BCORL1, BCR, BIRC3, BLM, BMPR1A, BRAF, BRCA1, BRCA1&2 Sequencing, BRCA2, BRIP1, BRWD3, BTK, CALR, CARD11, CBL, CBLB, CBLC, CCND1, CCND2, CCNE1, CD19, CD274, CD74, CDH1, CDK12, CDK4, CDK6, CDK8, CDK9, CDKN1A, CDKN1C, CDKN2A, CDKN2B, CEBPA, CHD1, CHD3, CHD8, CHEK1, CHEK2, COG5, CRADD, CREBBP, CRLF2, CRX, CSF1R, CSF3R, CTCF, CTNNA1, CTNNB1, CUX1, DAXX, DDR2, DDX41, DEPDC5, DICER1, DIS3L2, DNAJB1, DNMT3A, DOCK7, DPYD, EBF1, EED, EGFR, EGLN1, EIF3E, EML4, ENPP3, EP300, EPAS1, EPCAM, EPHA3, EPHA5, EPHB2, EPHB6, EPO, EPOR, ERBB2, ERBB3, ERBB4, ERCC2, ERG, ESR1, ESR2, ETV6, EZH2, FAM175A, FAM19A2, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FH, FKBP1A, FLT1, FLT3, FLT4, FOXA1, FOXR2, FUBP1, GAB2, GALNT12, GATA1, GATA2, GATA3, GEN1, GLI1, GLI3, GLTSCR1, GLTSCR2, GNA11, GNAQ, GNAS, GPC3, GREM1, GRIN2A, GRM3, Gynecological Oncology Pathway, GYNPTH, H3-3A /H3F3A, H3-3B /H3F3B, H3C2/HIST1H3B, HDAC4, HDAC9, HIF1A, HNF1A, HNRNPU, HOOK3, HRAS, HSPH1, ID3, IDH, IDH1, IDH2, IGF1R, IKZF1, IL7R, JAK1, JAK2, JAK3, KCNJ8, KDM2B, KDM6A, KDR, KIF5B, KIT, KLF4, KMT2A, KMT2C, KMT2D, KRAS, KTN1, LYST, MAP2K1 (MEK1), MAP2K2 (MEK2), MAP2K4, MAP7, MAPK1, MAX, MC1R, MCL1, MDM2, MDM4, MED12, MEGF6, MEN1, MET, microsatellite instability, MIOS, MITF, MLH1, MLH3, MN1, MPL, MRE11A, MSH2, MSH6, MTAP, MTOR, multigene panel, MUTYH, MYB, MYC, MYCL, MYCL1, MYCN, MYD88, MYOD1, NAB2, NAT2, NBN, next-generation sequencing, NF1, NF2, NKX2-1, NOTCH1, NOTCH2, NOTCH3, NPM1, NPRL2, NPRL3, NR4A3, NRAS, NRP1, NSD1, NT5C2, NTHL1, NTRK1, NTRK2, NTRK3, NUDT15, OFD1, paired tumor panel, PAK1, PALB2, PAX5, PBRM1, PDCD1LG2, PDGFRA, PDGFRB, PHF6, PHOX2B, PIGA, PIK3CA, PIK3CB, PIK3R1, PLCG2, PLK1, PLK2, PLK3, PLK4, PML, PMS2, POLD1, POLE, PPM1D, PPP1CB, precision medicine panel, precision oncology panel, PRKAR1A, PRPF40B, PRPS1, PTCH1, PTEN, PTPN11, PTPRD, QKI, RAC1, RAD21, RAD51B, RAD51C, RAD51D, RAF1, RARA, RASA1, RB1, RECQL, RELA, RET, RHEB, RICTOR, RINT1, RIT1, ROR1, ROS1, RPL10, RPL31, RPS15, RPS20, RPTOR, RRM1, RRM2, RSPO2, RSPO3, RUNX1, SAMD9L, SDHA, SDHB, SDHC, SDHD, SETBP1, SETD2, SF1, SF3B1, SH2B3, SHH, SIGLEC10, SLC25A13, SLX4, SMAD2, SMAD3, SMAD4, SMARCA4, SMARCB1, SMC1A, SMC3, SMO, SNAPC3, somatic panel, SPOP, SPRY4, SRC, SRP72, SRSF2, STAG2, STAT5B, STAT6, STK11, SUFU, SUZ12, TACC3, TACSTD2, TCF3, TERC, TERT, TET1, TET2, TET3, TFE3, TFG, TGFBR2, THOR, THORplex, TLX1, TMB, TMPRSS2, total mutation burden, TP53, TP73, TRAF7, TRRAP, TSC1, TSC2, TTYH1, tumor panel, U2AF1, U2AF2, UBR5, USP7, VHL, WRN, WT1, XRCC2, YAP1, ZBTB16, ZFTA/C11orf95, ZRSR2
The genes listed above are sequenced on an Illumina instrument to detect single nucleotide variants, small insertions and deletions, gene amplifications, and selected translocations
Gene Fusions and Rearrangements Detected*** (assay version 6)
ALK fusions (including ALK-EML4, ALK-KIF5B, ALK-TFG, ALK-C2orf44), BRAF fusions (common fusions only, including KIAA1549-BRAF), DNAJB1- PRKACA fusions, FGFR3 fusions, RET fusions (select fusions only), ROS1 fusions, NTRK1 fusions, NTRK2 fusions (select fusions only), NTRK3-ETV6 fusions, PML-RARA, RSPO2 fusions (select fusions only), RSPO3 fusions (select fusions only), TMPRSS2 fusions (select fusions only).
***Some fusions involving the genes listed above are not detectable by this method
Microsatellite Instability Analysis
Microsatellite instability (MSI) status is reported for all relevant cancer cases. MSI is detected using methods described in Salipate et al. 2014.
Total Mutation Burden Analysis
Total mutation burden (TMB) is estimated based on the number of somatic coding mutations per Mb sequenced.
- Reference Range
- See individual components
- Ref. Range Notes
No mutations detected
Ordering & Collection
- Specimen Type
- Tumor Tissue, Purified DNA, Bone Marrow, Peripheral Blood, accompanied by a PATHOLOGY REPORT for the tested tissue.
Requirements for Specimen Selection
- To ensure clinically relevant results, the most recent and/or metastatic sample is preferred to older specimens, provided sufficient tumor is present (see point 2).
- To ensure detection of all types of mutations there should be at least 10% tumor cells in the tissue area processed for DNA for mutation detection and 20% tumor cells for microsatellite instability evaluation. If there is more than one tissue block, please provide the block that has the greatest percentage of neoplastic nuclei.
- Tissue samples and pathology reports will be reviewed by directors upon receipt for acceptability prior to testing. Director consultation for tissue selection is available if needed (contact Genetics lab).
Send one of the following:
- Slides: 1 slide at 4-micron thickness stained with hematoxylin-and-eosin (H&E) AND 10 unstained, non-baked slides at 10-micron thickness (a minimum of 5 unstained slides is acceptable). Unstained slides can be on charged or uncharged slides.
- Tissue Blocks: Provide complete formalin-fixed tissue block containing tumor tissue. Tissue block will be returned at completion of testing.
- Fresh/frozen tissue: 5 microgram tissue in cell culture medium or frozen tissue stored at -20C. Tumor percentage will not be determined prior to sequencing studies.
NOTE: In order to ensure that enough DNA is obtained, the minimum acceptable tissue area is 10 square millimeters when ten 10-micron slides are supplied (1 cubic millimeter of tissue).
5 micrograms ANDa reference hematoxylin-and-eosin (H&E) stained slide and pathology report required.
1 to 2 mL Bone Marrow in LAVENDER TOP (EDTA) tube
6 mL blood in LAVENDER TOP (EDTA) tube.
Alternative specimens may be acceptable with approval (contact: 206-598-1149).
For ADD-ON after prior testing, contact Genetics lab.
We cannot accept decalcified samples or tissue samples treated with fixatives other than formalin.
- Tissue: 10 unstained slides (10-micron thickness) plus one H&E-stained slide.
- Extracted DNA: 5 microgram Bone Marrow: 2 mL
- Blood: 6 mL
- Tissue: 5 unstained slides (10-micron thickness) plus one H&E-stained slide.
- Extracted DNA: 100-250 nanograms Bone Marrow: 1 mL
- Blood: 3 mL
- Forms & Requisitions
Requisition Form and Ordering Instructions:
1. Fill out a Genetics Requisition Form
Providers with access to the UW implementation of Epic (i.e., FHCC, HMC, SCCA, UWMC, UWNW) may order this test using the order "UW Genetics and Solid Tumor Test Request." See tip sheet for more information (internal link).
2. Check "UW-OncoPlex™ Cancer Gene Panel"
3. Please enter any prior molecular testing results in the clinical history space provided
Genetics Preauthorization Form (preauthorization is only done for providers who are external to the UW system).
- Handling Instructions
Please attach a copy of the pathology report for the tumor sample being submitted. Please include the flow cytometry report for appropriate hematologic malignancy samples, such as those for acute myeloid leukemia (AML) or chronic lymphocytic leukemia (CLL).
requested: Amounts as noted above
minimum: Amounts as noted above
Tissue: Hold slides or tissue blocks at room temperature.
Outside Laboratory: Ship at room temperature.
Stability: unstained slides or tissue blocks stable at room temperature for at least 2 years.
Purified DNA: Refrigerate DNA specimens. Frozen is acceptable.
Blood or Bone Marrow: Refrigerate whole blood and/or bone marrow
Unacceptable Conditions: Frozen or clotted specimens
Stability (collection to initiation of testing): Ambient: 3 days; Refrigerated: 7 days
- Transport Temperature
- LIS Dept Code
- Genetics (GEN)
- Performing Location(s)
Attention: Genetics Lab
Clinical lab, Room NW220
University of Washington Medical Center
1959 NE Pacific Street
Seattle, WA 98195
Tel: 206-598–6429 M–F (7:30 AM–4:00 PM)
Lab email: firstname.lastname@example.org
Tel (EXOME only): 206-543-0459
Joe Bernal, email@example.com
Rebecca Gaulin, firstname.lastname@example.org
Angela Jacobson, MS, LGC email@example.com
Sarah Paolucci, MA, MS, LGC, firstname.lastname@example.org
Jenna Huey, MS, LGC, email@example.com
Sandra Coe, MS,LGC, firstname.lastname@example.org
Dru Leistritz, MS, LGC, email@example.com (EXOME testing only)
Variant Review Scientist
Ankita Jhuraney, PhD
Colin C. Pritchard, MD, PhD
Brian H. Shirts, MD, PhD
Christina Lockwood, PhD, DABCC
Stephen Salipante, MD, PhD
Eric Konnick, MD, MS
Niklas Krumm, MD,PhD
Vera Paulson, MD, PhD
Jillian Buchan, PhD, FACMG
- Results within 4-6 weeks, from sample receipt in laboratory.
- Available STAT?
Billing & Coding
- CPT codes
- Billing Comments
For additional test/billing information, see following page: UW-OncoPlex™ Cancer Gene Panel Billing.
For pricing information, contact Client Support Services 206-520-4600 or 800-713-5198.
We offer insurance pre-authorization services (preauthorization is only done for providers who are external to the UW system).
Email: firstname.lastname@example.org or call 1-855-320-4869 for more information.